Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 1, 2010, Pages 89-94

  Kappelle, Paul J W H ^a   Dallinga Thie, Geesje M ^b   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein B; atorvastatin; Diabetes mellitus; LDL subfractions; LDL cholesterol; Non HDL cholesterol; Remnant like particle cholesterol; Small dense LDL; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL DERIVATIVE; INSULIN; LOW DENSITY LIPOPROTEIN 1 CHOLESTEROL; LOW DENSITY LIPOPROTEIN 2 CHOLESTEROL; LOW DENSITY LIPOPROTEIN 3 CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; REMANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 71549131923     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.09.021     Document Type: Article

References (43)

1. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
2. Uusitupa M.I.J., Niskanen L.K., Siitonen O., Voutilainen E., and Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36 (1993) 1175-1184
3. Lehto S., Rönnemaa T., Haffner S.M., Pyörälä K., Kallio V., and Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46 (1997) 1354-1359
4. Syvanne M., and Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 Suppl 1 (1997) SI20-SI23
5. Feingold K.R., Grunfeld C., Pang M., Doerrier W., and Krauss R.M. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12 (1992) 1496-1502
6. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46 (2003) 733-749
7. Chan D.C., and Watts G.F. LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study?. Eur. J. Clin. Invest. 34 (2004) 719-722
8. Sacks F.M., and Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J. Clin. Endocrinol. Metab. 88 (2003) 4525-4532
9. Phillips N.R., Waters D., and Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88 (1993) 2762-2770
10. Schaefer E.J., McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Ordovas J.M., and Wilson P.W. Framingham Offspring Study. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25 (2002) 989-994
11. Kugiyama K., Doi H., Takazoe K., Kawano H., Soejima H., Mizuno Y., Tsunoda R., Sakamoto T., Nakano T., Nakajima K., Ogawa H., Sugiyama S., Yoshimura M., and Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99 (1999) 2858-2860
12. Cholesterol Treatment Trialists (CTT) collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
13. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care 32 Supplement 1 (2009) S29-S31
14. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., Hsia J., Breazna A., LaRosa J., Grundy S., and Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
15. Frost R.J., Otto C., Geiss H.C., Schwandt P., and Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87 (2001) 44-48
16. Geiss H.C., Otto C., Schwandt P., and Parhofer K.G. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 50 (2001) 983-988
17. Sone H., Takahashi A., Shimano H., Ishibashi S., Yoshino G., Morisaki N., Saito Y., Kawazu S., Teramoto T., Fujita T., Shiba T., Iwamoto Y., Kuzuya N., Akanuma Y., and Yamada N. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 71 (2002) 2403-2412
18. Wägner A.M., Jorba O., Bonet R., Ordóñez-Llanos J., and Pérez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 88 (2003) 3212-3217
19. Kazama H., Usui S., Okazaki M., Hosoi T., Ito H., and Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res. Clin. Pract. 59 (2003) 181-189
20. May H.T., Anderson J.L., Pearson R.R., Jensen J.R., Horne B.D., Lavasani F., Yannicelli H.D., and Muhlestein J.B. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am. J. Cardiol. 101 (2008) 486-489
21. Rizzo M., Rini G.B., and Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv. Ther. 24 (2007) 575-582
22. Stein E.A., Lane M., and Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81 4A (1998) 66B-69B
23. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., and Witztum J.L. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 51 (2008) 1512-1524
24. Berk-Planken I.I., Hoogerbrugge N., Jansen H., Princen H.M.G., Huisman M.V., van de Ree M.A., Stolk R.P., van Venrooij F.V., Banga J.D., Dallinga-Thie G., and DALI Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia - The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24 (2001) 1335-1341
25. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
26. Steinmetz J., Tarallo P., Fournier B., Caces E., and Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995) 337-342
27. Hoogerbrugge N., and Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 146 (1999) 167-174
28. Griffin B.A., Caslake M., Yip B., Tait G., Packard C.J., and Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83 (1990) 59-67
29. Campos E., Nakajima K., Tanaka A., and Havel R.J. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J. Lipid Res. 33 (1992) 369-380
30. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., Tanaka A., Tada N., Nakamura H., Campos E., and Havel R.J. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin. Chim. Acta 223 (1993) 53-71
31. van Hees A.M., Saris W.H., Dallinga-Thie G.M., Hul G.B., Martinez J.A., Oppert J.M., Stich V., Astrup A., Arner P., Sørensen T.I., and Blaak E.E. Fasting and postprandial remnant-like particle cholesterol concentrations in obese participants are associated with plasma triglycerides, insulin resistance, and body fat distribution. J. Nutr. 138 (2008) 2399-2404
32. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C., and ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am. J. Cardiol. 88 (2001) 265-269
33. Ballantyne C.M., Raichlen J.S., and Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J. Am. Coll. Cardiol. 52 (2008) 626-632
34. Kappelle P.J., Zwang L., Huisman M.V., Banga J.D., Sluiter W.J., Dallinga-Thie G.M., and Dullaart R.P.F. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert Opin. Ther. Targets 13 (2009) 743-751
35. Myerson M., Ngai C., Jones J., Holleran S., Ramakrishnan R., Berglund L., and Ginsberg H.N. Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J. Lipid Res. 46 (2005) 2735-2744
36. de Sauvage Nolting P.R., Twickler M.B., Dallinga-Thie G.M., Buirma R.J., Hutten B.A., and Kastelein J.J. Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia (ExPRESS) Study Group. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation 106 (2002) 788-792
37. Guérin M., Le Goff W., Lassel T.S., Van Tol A., Steiner G., and Chapman M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 282-288
38. van Venrooij F.V., Stolk R.P., Banga J.D., Sijmonsma T.P., van Tol A., Erkelens D.W., Dallinga-Thie G.M., and DALI Study Group. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 26 (2003) 1216-1223
39. de Vries R., Kerstens M.N., Sluiter W.J., Groen A.K., van Tol A., and Dullaart R.P.F. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 48 (2005) 1105-1113
40. Soedamah-Muthu S.S., Colhoun H.M., Thomason M.J., Betteridge D.J., Durrington P.N., Hitman G.A., Fuller J.H., Julier K., Mackness M.I., and Neil H.A. CARDS Investigators The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167 (2003) 243-255
41. Chung M., Lichtenstein A.H., Ip S., Lau J., and Balk E.M. Comparability of methods for LDL subfraction determination. Atherosclerosis 205 (2009) 342-348
42. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res. 43 (2002) 1363-1379
43. Adiels M., Boren J., Caslake M.J., Stewart P., Soro A., Westerbacka J., Wennberg B., Olofsson S.O., Packard C., and Taskinen M.R. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1697-1703